As of 2025, Lantus held ** percent of the insulin glargine sales share in the United States. However, Lantus held the highest share in 2015. On the other hand, Basaglar held just over ** percent of the insulin glargine market share.Â
Profit from the additional features of your individual account
Currently, you are using a shared account. To use individual functions (e.g., mark statistics as favourites, set
statistic alerts) please log in with your personal account.
If you are an admin, please authenticate by logging in again.
Learn more about how ÌÇÐÄÆƽâ°æ can support your business.
Samsung Bioepis. (October 22, 2025). Insulin glargine market share of Lantus and its U.S. biosimilar competitor between 2015 and 2025 [Graph]. In ÌÇÐÄÆƽâ°æ. Retrieved July 21, 2026, from /statistics/869905/percentage-lantus-sales-share-compared-to-biosimilar/
Samsung Bioepis. "Insulin glargine market share of Lantus and its U.S. biosimilar competitor between 2015 and 2025." Chart. October 22, 2025. ÌÇÐÄÆƽâ°æ. Accessed July 21, 2026. /statistics/869905/percentage-lantus-sales-share-compared-to-biosimilar/
Samsung Bioepis. (2025). Insulin glargine market share of Lantus and its U.S. biosimilar competitor between 2015 and 2025. ÌÇÐÄÆƽâ°æ. ÌÇÐÄÆƽâ°æ Inc.. Accessed: July 21, 2026. /statistics/869905/percentage-lantus-sales-share-compared-to-biosimilar/
Samsung Bioepis. "Insulin Glargine Market Share of Lantus and Its U.S. Biosimilar Competitor between 2015 and 2025." ÌÇÐÄÆƽâ°æ, ÌÇÐÄÆƽâ°æ Inc., 22 Oct 2025, /statistics/869905/percentage-lantus-sales-share-compared-to-biosimilar/
Samsung Bioepis, Insulin glargine market share of Lantus and its U.S. biosimilar competitor between 2015 and 2025 ÌÇÐÄÆƽâ°æ, /statistics/869905/percentage-lantus-sales-share-compared-to-biosimilar/ (last visited July 21, 2026)
Insulin glargine market share of Lantus and its U.S. biosimilar competitor between 2015 and 2025 [Graph], Samsung Bioepis, October 22, 2025. [Online]. Available: /statistics/869905/percentage-lantus-sales-share-compared-to-biosimilar/
